Rutgers Cancer Institute | Strategic Alliance Partners

As New Jersey’s only National Cancer Institute (NCI) – designated Comprehensive Cancer Center, Rutgers Cancer Institute offers the most advanced cancer treatment options including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex surgical procedures. Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy – many of which are not widely available – these cutting-edge therapies are available to adult and pediatric patients. Some of these treatments are fueled by onsite research in which physicians and scientists work side by side to advance our understanding of cancer and transform laboratory discoveries into clinical practice.

Connect with us:

Latest from Rutgers Cancer Institute

Dr Shah on the Effects of IVIG on Teclistamab-Associated Infection Risk in Myeloma

December 20, 2024

Video

Mansi R. Shah, MD, on the effects of IVIG on infections in recipients of teclistamab therapy for multiple myeloma.

NSABP B-51 Data Highlight Evolving Role of Radiation in Early-Stage Breast Cancer

August 25, 2024

Article

Bruce G. Haffty, MD, MS, discusses radiation therapy in node-positive breast cancer that becomes node negative after neoadjuvant chemotherapy.

Sarcoma Awareness Month 2024: Recognizing Symptoms, Scanning Patients Key to Diagnosis

July 30, 2024

Article

During Sarcoma Awareness Month, Adam C. Berger, MD, FACS, discusses the importance of timely scans and recognizing the symptoms of sarcoma.

Dr Mattes on the Mechanism of Action of Ipatasertib in HNSCC

June 20, 2024

Video

Malcolm Mattes, MD, discusses the CTEP 10492 trial of ipatasertib plus chemoradiotherapy in locally advanced head and neck squamous cell carcinoma.

Dr Matasar on the Design of the OLYMPIA-3 Trial in DLBCL

June 13, 2024

Video

Matthew Matasar, MD, discusses the design of the phase 3 OLYMPIA-3 trial of odronextamab plus CHOP in treatment-naive intermediate- or high-risk DLBCL.

Expert Commentary: Insights into Cancer Mutation Patterns

April 04, 2024

Article

Researchers at Rutgers Cancer Institute of New Jersey provided commentary on how changes in the structure of DNA influence the mutation patterns in cancer.

Exploring Disparities in Colorectal Cancer

March 30, 2024

Article

Health systems have put a stronger emphasis on making preventive care accessible, contributing to a reduction in colorectal cancer incidence and mortality.

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health Retains its Position as New Jersey’s Only National Cancer Institute-Designated Comprehensive Cancer Center

March 26, 2024

Article

Rutgers Cancer Institute of New Jersey along with RWJBarnabas Health was redesignated by the National Cancer Institute.

Dr Blackwood on the Significance of Early Breast Cancer Screenings

March 05, 2024

Video

M. Michele Blackwood, MD, FACS, discusses the significance of early cancer screenings.

Director of Oncology Services Northern Region Named to New Jersey’s Only NCI-Designated Comprehensive Cancer Center

February 22, 2024

Article

George Raptis, MD, MBA, begins role at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health.

RWJBarnabas Health and Rutgers Cancer Institute of New Jersey First in State Offering Novel Form of Liver Cancer Treatment

February 16, 2024

Article

Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health will offer hepatic artery infusion therapy for patients with liver tumors.

Future Perspectives on the Treatment Landscape for CLL

February 16, 2024

Video

A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in CLL.

Expert Insights into Investigation Therapies for CLL

February 16, 2024

Video

Expert oncologists explore emerging therapies being investigated in CLL, including BTKi degraders, CAR-T therapy, and bispecific antibodies, and discussed their potential impact in shaping the future of CLL treatment.

Rutgers Cancer Institute of New Jersey Unveils Leadership Enhancements for Next Era of Excellence

February 13, 2024

Article

Rutgers Cancer Institute of New Jersey has elevated 2 associate director functions to deputy director positions.

Emerging Data Surrounding Mechanisms of Resistance to Non-Covalent BTKis

February 09, 2024

Video

The expert panel discusses recent data regarding the mechanisms of resistance to non-covalent BTK inhibitors in CLL.

Role of Non-Covalent BTKis in R/R CLL: Updates from Ongoing BRUIN and Bellwave Trials

February 09, 2024

Video

Jacqueline Barrientos, MD, MS, discusses the role of non-covalent BTK inhibitors in R/R CLL and provided concise comments on the latest data, including insights from the ongoing BRUIN and Bellwave trials.

Treatment Resistance with Covalent BTKis: Translating Data into Clinical Practice

February 02, 2024

Video

Javier Pinilla, MD, PhD explores evidence on molecular mechanisms leading to resistance in second-generation BTK inhibitors for CLL, providing insights from recently presented data at ASH 2023.

Expert Insights into Navigating Cardiovascular Risks with BTKi Therapy

February 02, 2024

Video

A panel of expert oncologists explore the influence of hypertension risk and other cardiovascular AEs in guiding treatment selection with BTKis, sharing insights from ASH 2023.

Expert Perspectives on Navigating Treatment Selection with BTKis in CLL

January 26, 2024

Video

Faculty provide insights into the selection of BTK inhibitors, emphasizing the role of efficacy, toxicity, and quality of life data in treatment decisions, and exploring the impact of MAIC data.

Navigating BTKi Therapy in R/R CLL: Updates from ELEVATE-RR and ALPINE

January 26, 2024

Video

Panel experts examine considerations for BTKi-based strategies in R/R CLL, highlighting pivotal findings from head-to-head trials, including acalabrutinib vs ibrutinib in ELEVATE-RR and zanubrutinib vs ibrutinib in ALPINE, covering safety, quality of life, and extended follow-up data.